ImageneBio, Inc. (IMA)
| Market Cap | 46.54M -52.2% |
| Revenue (ttm) | n/a -77.1% |
| Net Income | -53.33M |
| EPS | -4.81 |
| Shares Out | 11.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,353 |
| Open | 4.050 |
| Previous Close | 4.050 |
| Day's Range | 4.050 - 4.210 |
| 52-Week Range | 3.880 - 8.950 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 18.00 (+339.02%) |
| Est. Earnings | Nov 11, 2026 |
About IMA
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Financial Performance
In 2025, ImageneBio's revenue was $800,000, a decrease of -77.14% compared to the previous year's $3.50 million. Losses were -$52.40 million, 8.29% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IMA stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 339.02% from the latest price.
News
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company's Board o...
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fire...
ImageneBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of ImageneBio (IMA) with a Buy rating and $28 price target ImageneBio is a clinical-stage biopharmaceutical company focused on developing therapies for immunological...
ImageneBio registers to sell 5.77M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.77M shares of common stock. The company is not selling any…
ImageneBio files $200M mixed securities shelf
16:28 EDT ImageneBio (IMA) files $200M mixed securities shelf
ImageneBio reports Q2 EPS (63c), consensus (98c)
“Imagene’s olevaprubart is now primed to emerge as the leading OX40 signal blockade program. With our continued progress in advanced clinical development, our conviction remains strong,” said Kristin ...
ImageneBio Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company up...
ImageneBio appoints Matt Robbins as general counsel
ImageneBio (IMA) announced the appointment of Matt Robbins as general counsel, effective July 7. Robbins joins the clinical-stage biotechnology company from Bright Peak Therapeutics, where he served a...
ImageneBio Appoints Matt Robbins as General Counsel
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies Brings more than 15 years of corporate, securities, and transaction...
Independent Medical Alliance Launches IMA Academy, Expanding Access to Expert-Led, CME-Accredited Medical Education
WASHINGTON--(BUSINESS WIRE)-- #Education--The Independent Medical Alliance (IMA) today announced the official launch of IMA Academy, a new medical education platform designed to provide healthcare pro...
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferie...
ImageneBio price target lowered to $24 from $30 at Leerink
Leerink analyst David Risinger lowered the firm’s price target on ImageneBio (IMA) to $24 from $30 and keeps an Outperform rating on the shares.
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update fo...
ImageneBio Announces $30 Million Private Placement
SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA)(“Imagene” or the “Company”) today announced it has entered into a definitive securities purchase agreement with certain ins...
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025,...
ImageneBio to Participate in Leerink Global Healthcare Conference
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at...
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive compl...
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to op...
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoi...
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/aut...
ImageneBio Quarterly report: Q2 2025
ImageneBio has published its Q2 2025 quarterly earnings report on July 24, 2025.
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph...
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (...
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glas...
ImageneBio Quarterly report: Q1 2025
ImageneBio has published its Q1 2025 quarterly earnings report on May 8, 2025.